Trombital Forte, 150 mg+30.39 mg 30 pcs

Creases aggregation, platelet adhesion and thrombosis by inhibiting the synthesis of thromboxane A2 in platelets. Antiplatelet effect lasts for 7 days after a single dose (more pronounced in men than in women).

Acetylsalicylic acid reduces lethality and risk of myocardial infarction in unstable angina, it is effective in primary prevention of cardiovascular diseases, especially in men over 40 years old and in secondary prevention of myocardial infarction.

Suppresses prothrombin synthesis in the liver and increases prothrombin time. Increases the fibrinolytic activity of the blood plasma and reduces the concentration of vitamin K-dependent clotting factors (II, VII, IX, X). Increases the risk of hemorrhagic complications during surgical interventions, increases the risk of bleeding during anticoagulant therapy.

Acetylsalicylic acid in high doses also has anti-inflammatory, analgesic and antipyretic effects.

In high doses, acetylsalicylic acid stimulates excretion of uric acid (disrupts its reabsorption in the renal tubules).

Blockade of cyclooxygenase-1 in gastric mucosa leads to inhibition of gastroprotective prostaglandins, which may cause mucosal ulceration and subsequent bleeding.

Magnesium hydroxide, which is part of the drug Trombital Forte, protects the gastrointestinal mucosa from the effects of acetylsalicylic acid.

Indications

Primary prevention of cardiovascular diseases such as thrombosis and acute heart failure in the presence of risk factors (e.g., diabetes, hyperlipidemia, arterial hypertension, obesity, smoking, old age).

Prevention of cardiovascular disease: recurrent myocardial infarction, blood vessel thrombosis.

Prevention of thromboembolism after surgical interventions on blood vessels (e.g., aorto-coronary bypass surgery, percutaneous transluminal coronary angioplasty, etc.).

Unstable angina (including suspected acute myocardial infarction).

Active ingredient

Composition

Active ingredients:

acetylsalicylic acid – 150.00 mg, magnesium

hydroxide – 30.39 mg.

Auxiliary substances:

microcrystalline cellulose – 24.15 mg,

corn starch – 19.00 mg,

potato starch – 4.00 mg,

magnesium stearate – 0.30 mg.

Shell:

hypromellose (hydroxypropyl methylcellulose 15 cPs) – 1.20 mg,

macrogol (polyglycol 4000) – 0.24 mg,

talc – 0.72 mg.

How to take, the dosage

The drug is taken orally with water. The tablet can be swallowed whole, chewed or crushed.

The drug is intended for long-term use. The duration of treatment with Trombital Forte is determined by the physician. One tablet of Trombital Forte contains 150 mg of acetylsalicylic acid.

If necessary, the daily dose of acetylsalicylic acid may be reduced to 75 mg, at the discretion of the physician (see section “Special information”). Primary prevention of cardiovascular diseases, such as thrombosis and acute heart failure in the presence of risk factors (e.g., diabetes mellitus, hyperlipidemia, arterial hypertension, obesity, smoking, old age) – 1 tablet once daily.

Prevention of cardiovascular diseases: repeated myocardial infarction, blood vessel thrombosis – 1 tablet once a day.

Prophylaxis of thromboembolism after surgical interventions on blood vessels (for example, aorto-coronary bypass surgery, percutaneous transluminal coronary angioplasty and others) – 1 tablet once a day.

Unstable angina pectoris (including suspected acute myocardial infarction) – 1 tablet once daily.

In unstable angina with suspected acute myocardial infarction, the first tablet should be chewed for faster absorption.

The drug should only be used according to the indication, route of administration, and dosage listed in the directions.

Interaction

Special Instructions

The drug should be used as prescribed by a physician.

The tablets of the drug Trombital Forte are film-coated, have no risks and are not intended to be divided, so if the doctor recommends reducing the daily dose of acetylsalicylic acid to 75 mg, then a switch to another drug containing 75 mg of acetylsalicylic acid in 1 tablet is required.

Acetylsalicylic acid may provoke bronchospasm, as well as causing attacks of bronchial asthma and other hypersensitivity reactions.

Risk factors include a history of bronchial asthma, hay fever, nasal polyposis, chronic respiratory disease, and allergic reactions to other drugs (e.g., skin reactions, itching, urticaria).

Acetylsalicylic acid may cause bleeding of varying severity during and after surgical interventions. Several days before the planned surgical intervention, the risk of bleeding should be assessed in comparison with the risk of ischemic complications in patients taking low-dose acetylsalicylic acid.

If the risk of bleeding is significant, acetylsalicylic acid should be temporarily discontinued. The combination of acetylsalicylic acid with anticoagulants, thrombolytics and antiplatelet agents is accompanied by an increased risk of bleeding.

Acetylsalicylic acid in low doses may provoke the development of gout in predisposed patients (who have reduced excretion of uric acid). The combination of acetylsalicylic acid with methotrexate is accompanied by an increased incidence of side effects on the hematopoietic organs.

High doses of acetylsalicylic acid have hypoglycemic effects, which should be kept in mind when prescribing it for patients with diabetes who are on oral hypoglycemic agents and insulin.

When combined use of systemic glucocorticosteroids and salicylates, it should be remembered that during treatment, the concentration of salicylates in blood is decreased, and after withdrawal of systemic glucocorticosteroids an overdose of salicylates is possible.

The combination of acetylsalicylic acid with ibuprofen is not recommended in patients with increased risk of cardiovascular disease: concomitant use with ibuprofen has decreased antiplatelet effects of acetylsalicylic acid at doses up to 300 mg, which reduces the cardioprotective effects of acetylsalicylic acid.

Extending the dose of acetylsalicylic acid beyond therapeutic doses is associated with the risk of gastrointestinal bleeding.

Long-term use of low doses of acetylsalicylic acid as antiplatelet therapy requires caution in elderly patients due to the risk of gastrointestinal bleeding.

The concomitant use of acetylsalicylic acid with alcohol increases the risk of gastrointestinal mucosal damage and prolonged bleeding time.

In long-term use of the drug, periodic general blood tests and fecal occult blood tests should be performed.

Impact on the ability to drive:

At the time of treatment with acetylsalicylic acid, caution should be exercised when driving vehicles and engaging in potentially hazardous activities that require increased concentration and rapid psychomotor reactions.

Features

Contraindications

Side effects

The adverse events listed below are distributed by frequency of occurrence according to the following gradation: very frequently (with an incidence greater than 1/10), frequently (with an incidence of at least 1/100 but less than 1/10), infrequently (with an incidence of at least 1/1000 but less than 1/100), rarely (with an incidence of at least 1/10000 but less than 1/1000), very rarely (with an incidence less than 1/10000), including individual reports.

Blood and lymphatic system disorders: very common – increased bleeding (hematoma, nasal bleeding, bleeding gums, bleeding from the urinary tract); rare – anemia; very rare – hypoprothrombinemia, thrombocytopenia, neutropenia, aplastic anemia, eosinophilia, agranulocytosis; unknown frequency – leukopenia.

There have been reports of serious cases of bleeding, which include gastrointestinal bleeding and cerebral hemorrhage (especially in patients with hypertension who have not reached target blood pressure and/or receive concomitant therapy with anticoagulants), which in some cases may be life-threatening.

Bleeding may lead to the development of acute or chronic posthemorrhagic/iron deficiency anemia (e.g., due to hidden bleeding) with corresponding clinical and laboratory signs and symptoms (asthenia, pallor, hypoperfusion). There have been reports of cases of hemolysis and hemolytic anemia in patients with severe forms of glucose-6-phosphate dehydrogenase deficiency.

Allergic reactions: common – urticaria, Quincke’s edema; infrequent – anaphylactic reactions, including angioedema; unknown frequency – skin rash, skin itching, rhinitis, nasal mucosal edema, cardio-respiratory distress syndrome, and severe reactions, including anaphylactic shock.

Nervous system disorders: frequently – headache, insomnia; infrequently – dizziness, somnolence; rarely – tinnitus, intracerebral hemorrhage; unknown frequency – hearing loss, which may be a sign of drug overdose (see section “Overdose”).

Respiratory system, thorax and mediastinum: often – bronchospasm.

Gastrointestinal tract disorders: very often – heartburn; often – nausea, vomiting; infrequent – abdominal pain, gastric and duodenal mucous membrane ulcers, including perforative (rare), gastrointestinal bleeding; rare – increased activity of “liver” enzymes; very rare – stomatitis, esophagitis, erosive lesions of the upper gastrointestinal tract, strictures, irritable bowel syndrome, colitis; unknown frequency – decreased appetite, diarrhea.

Urinary system disorders: unknown frequency – renal dysfunction and acute renal failure.

If you experience or worsen the side effects mentioned in the instructions, or if you notice any other side effects not mentioned in the instructions, tell your doctor.

Overdose

Pregnancy use

Similarities